The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses.
about
Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in AfricaMolecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEuropIntermittent presumptive treatment for malariaMitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systemsCombination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancyMathematical Modelling to Guide Drug Development for Malaria EliminationDuration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infantsModelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensityThe potential contribution of mass treatment to the control of Plasmodium falciparum malariaImpact of Schistosoma mansoni on malaria transmission in Sub-Saharan AfricaDuration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, GhanaModelling the epidemiological impact of intermittent preventive treatment against malaria in infants.Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria.Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children.2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials.Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children.Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasitesEffect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistanceThe evolution of drug-resistant malaria: the role of drug elimination half-lifeMalaria associated symptoms in pregnant women followed-up in BeninAntimalarial drug resistance and combination chemotherapy.Independent evolution of pyrimethamine resistance in Plasmodium falciparum isolates in Melanesia.Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant.Exploring the folate pathway in Plasmodium falciparum.Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications.Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine-Pyrimethamine Disposition Among Ugandan Pregnant Women.How antimalarial drug resistance affects post-treatment prophylaxis.Folate metabolism as a source of molecular targets for antimalarials.High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in BeninTherapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon.Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique.A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants.In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?Intermittent preventive treatment against malaria: an update.Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children.The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy.
P2860
Q24806194-81C95F0A-94D8-494F-834C-5BBCB6DBBBCDQ24807035-B671584D-0D4E-4BA0-BC16-39CCA03C2A47Q24809091-22D5FEB9-F3DE-406D-9042-E5B6599941B1Q27000750-C340CCB9-B735-48EE-BC2A-C5C97716C9DDQ27005614-2E7D39F1-BAD5-42B5-ACA0-4C221FD185E0Q28067367-30D49F30-9FED-43AB-9C01-22D30001E6E9Q28473083-88D4D1D0-3F46-4E7E-8E15-1B55A4AC514FQ28474141-0E2234A2-7ED6-4884-9A35-2373263A6416Q28478260-99A03529-0C4E-42C0-BA2D-9B2EEF4F1D46Q28543825-664DE63F-6838-4014-9D4B-4E4ED92B0538Q33336570-38C54C6C-E42B-496D-B037-C04F6FB7BEEAQ33351939-9850AF04-161A-4136-ACB4-5B3B064C360BQ33559071-4F73E4BD-52C6-43D2-8246-90BEE486D0E5Q33886209-AE7823BF-1DB3-4302-8F72-07ED2AB5600FQ33935223-A631A620-8B62-4814-92FA-10FFB63566DAQ33935430-CEA9BA85-508C-4DA5-B42E-B46C061450BBQ33979170-BAF6DAAC-B25E-4450-821F-4CE1B9F4DE2BQ33992235-A94188A3-D775-4C86-82C3-4623447A7DA4Q34655810-A4515BC6-CBC1-45F4-B819-CADD097A5D77Q34790559-6FCE816D-D7BE-44CA-B011-5A8493BEC65DQ35212414-B78F6D16-473B-4CF7-99B3-C9C1EA9DB46BQ35647764-E6F515B6-425F-4918-AD31-7324146DF2FCQ35827434-BFE755F9-35A1-45E3-B336-9168BBCFE6B8Q35945244-49128CE5-625D-4B44-98ED-5C38BB4C1875Q36104143-CF46FF8A-340E-4F8A-B7C9-47BAAB0DB8D1Q36178132-A6DC6355-6F82-48C0-B8AD-D2A9624F7D71Q36327790-4C9E69D9-54F2-45DC-B294-BCA5868C186CQ36478207-1AE36111-8359-4C86-9375-B85600A731C6Q36895753-45C45FC1-662B-4BB2-91CD-E61E96FB507EQ36940415-F4624880-49A6-4868-9951-F4AD7FC5FC17Q36981978-B5BF7757-438C-4AA8-86DF-BFB7CBAA9748Q37108868-F4791393-36E2-41FF-9CF7-85A9A11573BAQ37190605-D5C893F3-FCF2-40AF-92DC-83FB6AC4FF76Q37207985-03DC95C1-7C46-4EB9-990D-8B68BB258D6AQ37333178-2D0EA5F9-AC9A-4900-84CB-21C7C62C0181Q37685088-25C462A7-9327-4436-8854-1764BC96DD66Q37747411-FC476F4F-5294-45C4-BB47-2D562370AADEQ38152693-05214BAD-CD24-4DD9-BEE1-856181D003F4Q38882277-0DEB61AC-29CA-4C37-92BC-AF7CEFCB4E3CQ38882717-A6673845-F42E-4EE4-B801-EB705100565C
P2860
The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The efficacy of antifolate ant ...... and pharmacokinetic analyses.
@en
type
label
The efficacy of antifolate ant ...... and pharmacokinetic analyses.
@en
prefLabel
The efficacy of antifolate ant ...... and pharmacokinetic analyses.
@en
P2093
P1476
The efficacy of antifolate ant ...... and pharmacokinetic analyses.
@en
P2093
Watkins WM
Winstanley PA
P304
P356
10.1016/S0169-4758(97)01124-1
P577
1997-12-01T00:00:00Z